Report overview
Serum biomarkers are proteins generally detected in urine, blood, and Others bodily fluids produced by malignant cells or in reaction to presence/absence of malignant cells. Preferably, biomarkers should have at least one or more than one of the following properties: prompt detection of cancer within high risk population, diagnosis of specific type of cancer, prediction in its growth, screen its treatment response, and detect early recurrence.
This report contains market size and forecasts of Serum Cancer Biomarkers in global, including the following market information:
Global Serum Cancer Biomarkers Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Serum Cancer Biomarkers Market Sales, 2017-2022, 2023-2028, (MT)
Global top five Serum Cancer Biomarkers companies in 2021 (%)
The global Serum Cancer Biomarkers market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Hepatocellular Carcinoma Serum Biomarkers Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Serum Cancer Biomarkers include Roche, Pfizer, Novartis, Abbott, BD, Merck, Eli Lilly, Agilent Technologies and Boehringer Ingelheim, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Serum Cancer Biomarkers manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Serum Cancer Biomarkers Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Serum Cancer Biomarkers Market Segment Percentages, by Type, 2021 (%)
Hepatocellular Carcinoma Serum Biomarkers
Lung Cancer Serum Biomarkers
Pancreatic & Biliary Tract Cancer Serum Biomarkers
Breast Cancer Serum Biomarkers
Glioblastoma Serum Biomarkers
Others
Global Serum Cancer Biomarkers Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Serum Cancer Biomarkers Market Segment Percentages, by Application, 2021 (%)
Hospitals
Academic & Research Institutes
Ambulatory Surgical Centers
Others
Global Serum Cancer Biomarkers Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Serum Cancer Biomarkers Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Serum Cancer Biomarkers revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Serum Cancer Biomarkers revenues share in global market, 2021 (%)
Key companies Serum Cancer Biomarkers sales in global market, 2017-2022 (Estimated), (MT)
Key companies Serum Cancer Biomarkers sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Pfizer
Novartis
Abbott
BD
Merck
Eli Lilly
Agilent Technologies
Boehringer Ingelheim
AstraZeneca
Bristol-Myers Squibb
Novo Nordisk
Allergan
Gilead
